Literature DB >> 3088648

Naloxone does not affect cigarette smoking.

R Nemeth-Coslett, R R Griffiths.   

Abstract

In order to provide information about the hypothesis that endogenous opioids mediate the reinforcing properties of cigarette smoking, the present study examined the effects of naloxone, an opioid antagonist, on cigarette smoking in seven normal volunteers. The study used experimental procedures that had previously been shown sensitive for detecting the effects of other drugs, (including a nicotine antagonist) on smoking. Isolated subjects smoked their regular brand of cigarettes freely in a naturalistic laboratory environment while watching television or reading. Sixty minutes before each 2 h smoking session subjects received an IM injection of naloxone HCl (0.0625, 0.25, 1.0, or 4.0 mg/kg) or placebo. Each subject received each treatment three times in a mixed order across days. Naloxone did not significantly affect any measure of cigarette smoking including number of cigarettes, number of puffs, or expired air carbon monoxide level. Naloxone did, however, produce significant dose-related increases in subject ratings of yawning, stretching, and relaxation. The results of the present study provide no support for the endogenous opioid theory of smoking reinforcement.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3088648     DOI: 10.1007/bf00174355

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  18 in total

1.  Effects of mecamylamine on human cigarette smoking and subjective ratings.

Authors:  R Nemeth-Coslett; J E Henningfield; M K O'Keeffe; R R Griffiths
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

2.  Neuroendocrine reactivity to nicotine in smokers.

Authors:  O F Pomerleau; J B Fertig; L E Seyler; J Jaffe
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

3.  Effects of ethanol on cigarette smoking by volunteers without histories of alcoholism.

Authors:  J E Henningfield; L D Chait; R R Griffiths
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

4.  Differential control of puff duration and interpuff interval in cigarette smokers.

Authors:  L D Chait; R R Griffiths
Journal:  Pharmacol Biochem Behav       Date:  1982-07       Impact factor: 3.533

5.  Disposition of naloxone: use of a new radioimmunoassay.

Authors:  B A Berkowitz; S H Ngai; J Hempstead; S Spector
Journal:  J Pharmacol Exp Ther       Date:  1975-12       Impact factor: 4.030

6.  Cigarette smoking and subjective response in alcoholics: effects of pentobarbital.

Authors:  J E Henningfield; L D Chait; R R Griffiths
Journal:  Clin Pharmacol Ther       Date:  1983-06       Impact factor: 6.875

7.  Effects of methadone on human cigarette smoking and subjective ratings.

Authors:  L D Chait; R R Griffiths
Journal:  J Pharmacol Exp Ther       Date:  1984-06       Impact factor: 4.030

8.  Buprenorphine effects on cigarette smoking.

Authors:  N K Mello; S E Lukas; J H Mendelson
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

9.  The human pharmacology and abuse potential of N-allylnoroxymorphone (naloxone).

Authors:  D R Jasinski; W R Martin; C A Haertzen
Journal:  J Pharmacol Exp Ther       Date:  1967-08       Impact factor: 4.030

10.  Diazepam and methadone interactions in methadone maintenance.

Authors:  K L Preston; R R Griffiths; M L Stitzer; G E Bigelow; I A Liebson
Journal:  Clin Pharmacol Ther       Date:  1984-10       Impact factor: 6.875

View more
  16 in total

1.  Naltrexone attenuation of conditioned but not primary reinforcement of nicotine in rats.

Authors:  Xiu Liu; Matthew I Palmatier; Anthony R Caggiula; Alan F Sved; Eric C Donny; Maysa Gharib; Sheri Booth
Journal:  Psychopharmacology (Berl)       Date:  2008-09-21       Impact factor: 4.530

Review 2.  The opioid receptors as targets for drug abuse medication.

Authors:  Florence Noble; Magalie Lenoir; Nicolas Marie
Journal:  Br J Pharmacol       Date:  2015-06-26       Impact factor: 8.739

3.  Nicotine gum: dose-related effects on cigarette smoking and subjective ratings.

Authors:  R Nemeth-Coslett; J E Henningfield; M K O'Keeffe; R R Griffiths
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

Review 4.  Advances in non-nicotine pharmacotherapy for smoking cessation.

Authors:  L S Covey; M A Sullivan; J A Johnston; A H Glassman; M D Robinson; D P Adams
Journal:  Drugs       Date:  2000-01       Impact factor: 9.546

Review 5.  Neurobiological mechanisms involved in nicotine dependence and reward: participation of the endogenous opioid system.

Authors:  Fernando Berrendero; Patricia Robledo; José Manuel Trigo; Elena Martín-García; Rafael Maldonado
Journal:  Neurosci Biobehav Rev       Date:  2010-02-16       Impact factor: 8.989

Review 6.  Opioid antagonists for smoking cessation.

Authors:  Sean P David; Tim Lancaster; Lindsay F Stead; A Eden Evins; Judith J Prochaska
Journal:  Cochrane Database Syst Rev       Date:  2013-06-06

7.  Naltrexone reduces the relative reinforcing value of nicotine in a cigarette smoking choice paradigm.

Authors:  Margaret Rukstalis; Christopher Jepson; Andrew Strasser; Kevin G Lynch; Kenneth Perkins; Freda Patterson; Caryn Lerman
Journal:  Psychopharmacology (Berl)       Date:  2005-01-29       Impact factor: 4.530

8.  Naloxone precipitates nicotine abstinence syndrome in the rat.

Authors:  D H Malin; J R Lake; V A Carter; J S Cunningham; O B Wilson
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

Review 9.  Novel pharmacological approaches for treating tobacco dependence and withdrawal: current status.

Authors:  August R Buchhalter; Reginald V Fant; Jack E Henningfield
Journal:  Drugs       Date:  2008       Impact factor: 9.546

10.  Subjective correlates of cigarette-smoking-induced elevations of peripheral beta-endorphin and cortisol.

Authors:  D G Gilbert; C J Meliska; C L Williams; R A Jensen
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.